Suggested table of clinical case studies (to include in article): columns for patient phenotype (age, BMI, diagnosis), peptide used (dose, duration), metabolic outcomes (weight change, HOMA-IR), reproductive outcomes (ovulation, oocyte yield, pregnancy), adverse events, and follow-up duration, such as PCOS, obesity-associated anovulation, poor ovarian response, and metabolic syndrome
Those who suspect thyroid dysfunction, based on family history or undiagnosed symptoms, can also benefit greatly by undergoing advanced diagnostics and early intervention strategies
The dermatomes of the human body
Compounded semaglutide is a synthetic glucagon-like peptide-1 (GLP-1) receptor agonist used for chronic weight management, along with a reduced calorie diet and increased physical activity, for people with an initial body mass index (BMI) of: 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
It is important to understand that every medication can have side effects